AbbVie, Inc. (ABBV)
256.46
-3.75
(-1.44%)
USD |
NYSE |
Sep 04, 16:00
256.40
-0.06
(-0.02%)
Pre-Market: 20:00
AbbVie Research and Development Expense (Quarterly) : 2.344B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.344B |
| March 31, 2026 | 2.472B |
| December 31, 2025 | 2.579B |
| September 30, 2025 | 2.319B |
| June 30, 2025 | 2.131B |
| March 31, 2025 | 2.067B |
| December 31, 2024 | 2.298B |
| September 30, 2024 | 2.13B |
| June 30, 2024 | 1.948B |
| March 31, 2024 | 1.939B |
| December 31, 2023 | 1.922B |
| September 30, 2023 | 1.722B |
| June 30, 2023 | 1.732B |
| March 31, 2023 | 2.292B |
| December 31, 2022 | 1.781B |
| September 30, 2022 | 1.61B |
| June 30, 2022 | 1.608B |
| March 31, 2022 | 1.488B |
| December 31, 2021 | 1.811B |
| September 30, 2021 | 1.655B |
| June 30, 2021 | 1.784B |
| March 31, 2021 | 1.731B |
| December 31, 2020 | 1.821B |
| September 30, 2020 | 1.575B |
| June 30, 2020 | 1.406B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.379B |
| December 31, 2019 | 1.542B |
| September 30, 2019 | 1.255B |
| June 30, 2019 | 1.291B |
| March 31, 2019 | 1.289B |
| December 31, 2018 | 1.395B |
| September 30, 2018 | 1.268B |
| June 30, 2018 | 1.322B |
| March 31, 2018 | 1.244B |
| December 31, 2017 | 1.408B |
| September 30, 2017 | 1.228B |
| June 30, 2017 | 1.223B |
| March 31, 2017 | 1.135B |
| December 31, 2016 | 1.185B |
| September 30, 2016 | 1.052B |
| June 30, 2016 | 1.056B |
| March 31, 2016 | 946.00M |
| December 31, 2015 | 1.002B |
| September 30, 2015 | 1.40B |
| June 30, 2015 | 888.00M |
| March 31, 2015 | 811.00M |
| December 31, 2014 | 879.00M |
| September 30, 2014 | 812.00M |
| June 30, 2014 | 834.00M |
| March 31, 2014 | 772.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 461.70M |
| Gilead Sciences, Inc. | 1.69B |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Amgen, Inc. | 1.868B |
| REGENXBIO, Inc. | 52.33M |